Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.39 |
| ▸ | CACNB1 | Q02641 | 4/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | BCL2 | P10415 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977045 | 0.86 | CACNA2D1 (0.41) | CACNA2D1CACNA1BCACNB1CACNA1CSLC6A9 | |
| SCHEMBL2909614 | 0.86 | CACNA2D1 (0.39) | CACNA2D1CACNA1BCACNB1CACNA1CCYP3A4 | |
| SCHEMBL2906523 | 0.85 | HSD17B1 (0.40) | CACNA2D1CACNA1BCACNB1CACNA1CCYP3A4 | |
| SCHEMBL1993289 | 0.83 | MAPT (0.39) | CACNA2D1CACNA1BCACNB1CACNA1CSLC6A9 | |
| SCHEMBL2906645 | 0.82 | SLC6A9 (0.36) | CACNA2D1CACNA1BCACNB1CACNA1CCYP3A4 | |
| SCHEMBL1996083 | 0.82 | GRM5 (0.40) | MEN1KMT2ATSHRTDP1LMNA | |
| SCHEMBL4927549 | 0.81 | GPR84 (0.37) | CACNA2D1CACNA1BCACNB1CACNA1CCYP3A4 | |
| SCHEMBL2912813 | 0.81 | LMNA (0.41) | CACNA2D1CACNA1BCACNB1CACNA1CSLC6A9 | |
| SCHEMBL2138820 | 0.81 | CYP3A4 (0.55) | CACNA2D1CACNA1BCACNB1CACNA1CCYP3A4 | |
| Drinabant SCHEMBL684143 | 0.81 | CYP3A4 (0.36) | CACNA2D1CACNA1BCACNB1CACNA1CCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263722-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA SA (FR) | 2010-08-25 | — | — | EP | claimed |
| EP-1328269-B1 | ASSOCIATION OF A CB1 RECEPTOR ANTAGONIST AND SIBUTRAMIN FOR TREATING OBESITY | AVENTIS PHARMA SA (FR) | 2004-05-26 | — | — | EP | claimed |
| JP-2003525270-A | — | — | 2003-08-26 | — | — | JP | claimed |
| EP-1328269-A2 | ASSOCIATION OF THE CB1 RECEPTOR ANTAGONIST AND A SIBUTRAMIN FOR TREATING OBESITY | Aventis Pharma S.A. (FR) | 2003-07-23 | — | — | EP | claimed |
| CN-1418192-A | Pharmaceutical compositions containing azetidine derivatives novel azetidine derivatives and preparation thereof | AVENTIS PHARMA SA (FR) | 2003-05-14 | — | — | CN | claimed |
| EP-1263722-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | Aventis Pharma S.A. (FR) | 2002-12-11 | — | — | EP | claimed |
| US-20020091114-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | AVENTIS PHARMA S.A. (FR) | 2002-07-11 | — | — | US | claimed |
| WO-2002028346-A2 | ASSOCIATION OF THE CB1 RECEPTOR ANTAGONIST AND SIBUTRAMIN, FOR TREATING OBESITY | AVENTIS PHARMA S.A. (FR) | 2002-04-11 | — | — | WO | claimed |
| US-6355631-B1 | TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA | AVENTIS PHARMA S.A. (FR) | 2002-03-12 | — | — | US | claimed |
| WO-2001064634-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | claimed |
| EP-1263722-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA SA (FR) | 2010-08-25 | — | — | EP | disclosed |
| US-20080058381-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | AVENTIS PHARMA S.A. (FR) | 2008-03-06 | — | — | US | disclosed |
| US-7148258-B2 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | AVENTIS PHARMA S.A. (FR) | 2006-12-12 | — | — | US | disclosed |
| US-20060258709-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | AVENTIS PHARMA S.A. (FR) | 2006-11-16 | — | — | US | disclosed |
| US-7037944-B2 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | AVENTIS PHARMA S.A. (FR) | 2006-05-02 | — | — | US | disclosed |
| EP-1263722-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | Aventis Pharma S.A. (FR) | 2002-12-11 | — | — | EP | disclosed |
| US-20020091114-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | AVENTIS PHARMA S.A. (FR) | 2002-07-11 | — | — | US | disclosed |
| WO-2002028346-A2 | ASSOCIATION OF THE CB1 RECEPTOR ANTAGONIST AND SIBUTRAMIN, FOR TREATING OBESITY | AVENTIS PHARMA S.A. (FR) | 2002-04-11 | — | — | WO | disclosed |
| US-6355631-B1 | TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA | AVENTIS PHARMA S.A. (FR) | 2002-03-12 | — | — | US | disclosed |
| WO-2001064634-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058381-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | CNR2, CNR1, GPR119 | CACNA2D1 3229/4885CACNA1B 522/4885CACNB1 1430/4885 |
| US-20060258709-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | CNR2, CNR1, GPR119 | CACNA2D1 3229/4885CACNA1B 522/4885CACNB1 1430/4885 |
| US-20020091114-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | CNR2, CNR1, GPR119 | CACNA2D1 3229/4885CACNA1B 522/4885CACNB1 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.